Xentuzumab
Xentuzumab Uses, Dosage, Side Effects, Food Interaction and all others data.
Xentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
| Trade Name | Xentuzumab |
| Generic | Xentuzumab |
| Xentuzumab Other Names | Xentuzumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Xentuzumab
